HUMAN ISLET CELL TRANSPLANTATION FOR REVERSAL OF TYPE I DIABETES MELLITUS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 I型胰岛素依赖型糖尿病仅在美国就影响了大约80万人。尽管开发了外源性胰岛素和评估其给药方式的多个心得安，但由于缺乏稳定的血糖稳态，I型糖尿病患者遭受多种并发症。I型糖尿病患者通常只有胰腺内分泌功能缺陷，因此只需要替换朗格汉斯胰岛。胰岛移植是一种生物替代策略，它试图取代朗格汉斯人产生胰岛素的胰岛，并代表着一种潜在的疾病过程的治疗方法。这项研究的目的是确定胰岛移植，通过正常的胰腺内分泌轴，是否可以在连续10名I型糖尿病患者中实现胰岛素独立或显著减少胰岛素需求。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Type I insulin-dependent diabetes mellitus affects approximately 800,000 people in the U.S. alone. Despite the development of exogenous insulin and multiple portocols evaluating its mode of delivery, type I diabetics suffer multiple complications due to the lack of consistent glucose homeostasis. Type I diabetics usually only have deficiency in the endocrine function of the pancreas, and therefore only require replacement of the Islets of Langerhans. Pancreatic islet transplantation is a biologic replacement strategy that attempts to replace the insulin producing Islets of Langerhans and represents a potential cure for the disease process. The goal of this study is to determine if pancreatic islet transplantation, via the normal endocrine axis of the pancreas, can achieve either insulin independence or a significant decrease in insulin requirements in 10 consecutive type I diabetic patients.